For most BrD members, their level rarely correlates with tumor patients' survival, with only nine members (BRPF1, SMARCA2, BAZ1A, BAZ1B, ATAD2, TRIM28, SP100, SP110 and SP140) being significantly associated with either better or worse survival of at least five distinct tumor types. This evidence concerns the gene SP110 and neoplasm.